Objective

To evaluate the efficacy of the Defend 400 at reducing aerosolized Staphylococcus epidermidis, a surrogate for Staphylococcus aureus, MRSA and Micrococcus luteus.

Methodology

The environmental chamber used for this study was 30m³ in size and designed to replicate a room setting.

The bio-aerosol was generated using a 24-jet Collison nebuliser operated with a purified filtered air supply.

The bio-aerosol samples were collected at 15-minute intervals in sterile SKC BioSampler impingers to determine the chamber concentration.

Summary of Results

The Defend 400 achieved greater than a log-4 reduction (>99.99%) of Staphylococcus epidermidis after 45 minutes.